AstraZeneca has reported positive results from the efzimfotase alfa Phase III clinical trial programme for hypophosphatasia ...

Actinogen anticipates final topline efficacy and safety results for the full 36-week treatment period in November 2026.

Three-fourths of patients have 70-75% improvement at 16 weeks with zasocitinib, envudeucit ...

There are currently no FDA-approved drugs for treating the disorder ...

High-risk localized prostate cancer treated with neoadjuvant LHRH agonist/antagonist and enzalutamide plus the glucocorticoid receptor antagonist relacorilant versus placebo. This is an ASCO Meeting ...

In an effort to increase access to evidence-based interventions to help manage anxiety and depression, Mass General Brigham ...

Whole-blood transfusion has recently gained favor in the management of severe hemorrhage; however, data from large clinical trials evaluating its clinical effectiveness and safety are lacking. We ...

BACKGROUND: Medically tailored meals (MTM) have unanswered implementation questions. Providing MTM for a specific individual, ...

A device designed to capture more TAVR procedural debris proves noninferior to an existing device in a large trial, but the ...

Idiopathic normal-pressure hydrocephalus is a neurologic disorder characterized by impaired gait, balance, cognition, and bladder control in older adults. The disorder is treated with shunt surgery, ...

Thought LeadersAoife Hayes, Kevin O'Regan & Julie ScanlonClinical Trials Assitant, Operations Manager & Quality Assurance ManagerAtlantia Clinical Trials Food clinical trials may not be as familiar to ...